Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 2Phase EARLY_PHASE1 2Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1Endocrine 1CNS 1

Conditions

Multiple Myeloma 444Neoplasms, Plasma Cell 77Recurrence 62Lymphoma 52Lymphoma, Non-Hodgkin 48Leukemia 43Hodgkin Disease 43Leukemia, Myeloid, Acute 42Myelodysplastic Syndromes 37Leukemia, Lymphocytic, Chronic, B-Cell 35Precursor Cell Lymphoblastic Leukemia-Lymphoma 34Lymphoma, Mantle-Cell 29Lymphoma, Large B-Cell, Diffuse 29Lymphoma, Follicular 27Hematologic Neoplasms 24Burkitt Lymphoma 24Immunoglobulin Light-chain Amyloidosis 22Myeloproliferative Disorders 21Lymphoma, B-Cell, Marginal Zone 21Waldenstrom Macroglobulinemia 18Lymphoma, Large-Cell, Immunoblastic 18Neoplasms 17Lymphoma, T-Cell, Cutaneous 16Lymphoma, Large-Cell, Anaplastic 14Leukemia, Myelomonocytic, Chronic 14Leukemia, Myelogenous, Chronic, BCR-ABL Positive 14Sezary Syndrome 13Mycosis Fungoides 13Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 12Leukemia, Myeloid, Accelerated Phase 12

Interventions

ixazomib 1Dexamethasone 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Alzheimer Disease × Plasma cell × Clear all
NCT03236792 2022-09-29

Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis

Icahn School of Medicine at Mount Sinai

Phase 1/2 Completed
28 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Alzheimer Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡